key: cord-0783129-ul848ybb
authors: Kuchinski, Kevin S.; Nguyen, Jason; Lee, Tracy D.; Hickman, Rebecca; Jassem, Agatha N.; Hoang, Linda M.N.; Prystajecky, Natalie A.; Tyson, John R.
title: Mutations in emerging variant of concern lineages disrupt genomic sequencing of SARS-CoV-2 clinical specimens
date: 2021-10-29
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.10.050
sha: 542c47c61b2d9117048f64280a73aee8908731da
doc_id: 783129
cord_uid: ul848ybb

Mutations in emerging SARS-CoV-2 lineages can interfere with laboratory methods used to generate viral genome sequences for public health surveillance. We have identified 20 mutations that are widespread in variant of concern lineages and affect widely used sequencing protocols by the ARTIC network and Freed et al.. We show how three of these mutations disrupted sequencing of P.1 lineage specimens during a recent outbreak in British Columbia, Canada, and we provide laboratory validation of protocol modifications that restored sequencing performance. Our findings indicate that genomic sequencing protocols require immediate updating to address emerging mutations. This work also suggests that routine monitoring and protocol updates will be necessary as SARS-CoV-2 continues to evolve. The bioinformatic and laboratory approaches used here provide guidance for this kind of assay maintenance.

Mutations in emerging variant of concern lineages disrupt genomic sequencing of

Genomic sequencing of SARS coronavirus-2 (SARS-CoV-2) has played a crucial role in managing the on-going COVID-19 pandemic. This is especially true for variant of concern (VOC) lineages that have emerged globally since December 2020 (Chand et al. 2020; Cherian et al. 2021; Faria et al. 2021; Tegally et al. 2021a Tegally et al. , 2021b Rambault et al. 2020) .

Genomic sequencing has been instrumental in detecting and characterizing these lineages, tracking their global spread, and identifying local cases to control transmission.

Due to low quantities of viral genomic material in typical clinical specimens, the SARS-CoV-2 genome must be enriched for high-throughput sequencing. This is commonly done by multiplex PCR with numerous primer pairs tiled across the viral genome (Freed et al. 2020; Quick et al. 2017; Tyson et al. 2020) . The performance of these primer schemes can be disrupted by mutations arising in emerging viral lineages. These mutations inhibit the amplification of certain amplicons and reduce the amount of sequencing data generated across affected areas of the genome. At best, this necessitates over-sequencing specimens to compensate for areas with reduced sequencing depth, thereby increasing cost and reducing throughput. At worst, this causes inaccurate nucleotide base calls or gaps in the genome sequence. This undermines public health surveillance by interfering with lineage identification and obscuring genomic linkages between outbreak specimens.

We used a previously published bioinformatic pipeline called PCR_strainer to assess whether current VOC lineages contain mutations impacting two widely used sequencing primer schemes (Kuchinski et al. 2020) . We analyzed 27,244 recent, complete, high-quality genome sequences from lineages B.1.1.7, B.1.351, P.1, and B.1.617+ submitted to GISAID from laboratories around the world. All primer site variants present in at least 15% of their lineage's genome sequences are reported in Table 1 . We identified 15 primer site variants affecting the popular, commercially available ARTIC version 3 protocol (Tyson et al. 2020 ).

We also identified 5 mutated primer sites affecting the protocol by Freed et al. favoured by some laboratories for its longer amplicon size (Freed et al. 2020 (Table 1) . Compared to non-P.1 lineage specimens, median depths of coverage across these amplicons were reduced up to 32-fold. Genome sequences from 907 local P.1 lineage specimens were analyzed with PCR_strainer, confirming that the same mutations identified above in primers 21_LEFT, 24_RIGHT, and 25_RIGHT were present in 99.4%, 100%, and 95.8% of local sequences respectively. Figure 1B) . We then sequenced 373 clinical specimens with both non-spiked and spiked primer pools. Using these paired data, we calculated changes in depth of coverage across the affected amplicons for each specimen. We observed that the spiked primers pools significantly improved depth of coverage for all three impacted amplicons without detrimental effects on non-P.1 lineages ( Figure 1C ).

From these analyses, we concluded that the established amplicon sequencing protocols, like ARTIC version 3 and Freed et al., need immediate updates to address numerous prevalent mutations in VOC lineages. We have shown that spike-in primers can restore performance for impacted amplicons, but we caution that these spike-in primers are likely a temporary measure. As new SARS-CoV-2 lineages continue to emerge, multiplex PCR amplificationbased sequencing protocols will need to evolve alongside their viral target.

This principle was demonstrated in the months following the work presented above. B.1.617+ lineages, collectively renamed "delta" by the WHO, went from representing only a handful of cases in British Columbia to being pre-dominant. We assessed 388 specimens from local delta lineage specimens with PCR_strainer (Supplemental Table 1 (Table 1) . We also noted that an additional, less prevalent primer site mutation had emerged in delta lineages in the intervening months. The mutation in Amplicon 5's left primer had no meaningful impact on depth of coverage, which was not surprisingly given its location in the middle of the oligo (Supplemental Figure 1) . The mutations in Amplicon 27's left and right primers both caused reduced depth of coverage for these amplicons, but not to the same magnitude as the primer site mutations impacting P.1 lineages discussed above (Supplemental Figure 1) .

Emerging lineages must be monitored for disruptive mutations so that primer schemes can be updated routinely. As we have demonstrated here, spike-in primers can be effective stopgaps to maintain performance between major redesigns. The PCR_strainer pipeline can facilitate both tasks by screening tens-of-thousands of genome sequences and identifying relevant mutations.

We thank the dedicated staff at the BCCDC PHL for processing and sequencing SARS-CoV-2 clinical specimens, especially the Molecular Microbiology and Genomics program for optimizing genomics methods and the Bacteriology and Mycology program for routine sequencing of clinical specimens. We also thank the analytical staff for routine bioinformatic analysis.

This work was conducted under a surveillance mandate, authorized by the Provincial Health Officer of British Columbia under the Health Act, without requirement for research ethics board review. mmc2.docx mmc3.xlsx 373 clinical specimens, collected during Mar and April 2021 in British Columbia, Canada, were sequenced using the Freed et al. primers . Normalized mean depths of coverage are shown for three amplicons affected by mutations in primer sites (mean depth of coverage across each library's most deeply sequenced amplicon was used for normalization). B) Amplicon drop-out was corrected by spiking in supplemental primers. 24 clinical specimens were sequenced with non-spiked and spiked primer pools, then changes in normalized mean depth of coverage was calculated for the three affected amplicons. Supplemental primers were spiked in at the same molarity as original primers. Primer 24_LEFT_P.1 was also assayed at two-times and four-times molarity after one-times molarity did not significantly improve performance. C) Spiked primer pools had no detrimental effects on non-P1 lineages. 373 clinical specimens were sequenced with non-spiked and spiked primer pools containing primers 21_RIGHT_P.1 and 25_LEFT_P.1 at one-times molarity and primer 24_LEFT_P.1 at four-times molarity. Changes in normalized mean depth of coverage were calculated for the three affected amplicons. Table 1 : Nucleotide mismatches between SARS-CoV-2 variant of concern lineages and primers from ARTIC version 3 and Freed et al. protocols. Global sequences from variant of concern lineages were downloaded from GISAID, comprising 8,353 B.1.1.7 sequences, 3,025 B.1.351 sequences, 9,202 P.1 sequences, and 6,664 B.1.617+ sequences. All sequences were categorized as complete and high-coverage by GISAID (>29 kb, <1% Ns, <0.05% novel amino acid substitutions, and verified insertion/deletions only). All sequences were submitted before May 22, 2021. Lineages B.1.351, B.1.617+, and P.1+, sequences were collected after April 1, 2021, and lineage B.1.1.7 sequences collected after May 7, 2021. Sequence details and submitting laboratories, who we gratefully acknowledge for their contributions, are provided in Supplemental S1. Primer site variants were identified using the PCR_strainer pipeline with default parameters. Primer site variants were only reported if they were present in at least 15% of their lineage's sequences. A longer table is provided as Supplemental Table S2 , which reports all variants present in at least 1% of genomes within a lineage. Primer site variant sequences are provided in 'oligo sense', i.e. the reverse complement of the primer site and the sequence that the perfectly identical primer would have for the targeted location. Lower case bases in the primer site variant sequences indicate mismatches with the assay's original primer sequence.

Lineage Primer Name Primer site variant sequence (5' to 3')

Investigation of Novel SARS-CoV-2 variant 2020: technical briefing #1

Convergent evolution of SARS-CoV-2 spike mutations

the second wave of COVID-19 in Maharashtra, India. bioRxiv

Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings

Rapid and inexpensive whole-genome sequencing of SARS-CoV-2 using 1200 bp tiled amplicons and Oxford Nanopore Rapid Barcoding

Assessing oligonucleotide designs from early lab developed PCR diagnostic tests for SARS-CoV-2 using the PCR_strainer pipeline

Multiplex PCR method for MinION and Illumina sequencing of Zika and other virus genomes directly from clinical samples

Preliminary genomic characterisation of an emergent SARS-CoV-2 lineages in the UK defined by a novel set of spike mutations

Detection of a SARS-CoV-2 variant of concern in South Africa

Sixteen novel lineages of SARS-CoV-2 in South Africa

Improvements to the ARTIC multiplex PCR method for SARS

genome sequencing using nanopore

The authors have none to declare.

This work was funded in part by the Canadian COVID genomics network (CanCOGeN).